Keywords: Diagnosis/Prediction, Diffusion/other diffusion imaging techniques, Brain, gray matter, white matter
Motivation: Bottom-up energy budgets provide a way to quantify electrical activity in the brain using metabolic imaging. However, existing models are not patient-specific, instead using generalized neural cell counts, preventing direct measures of cognitive activity in the brain.
Goal(s): Our goal was to use a convolutional neural network (CNN) to demonstrate the possibility of predicting individualized neural cell counts.
Approach: Multi-modal MRI from nine patients was used to model neural and synaptic density predictions, which were compared to silver standard counts using correlation coefficient in a cross-validation study.
Results: The model demonstrates an ability to predict patient-specific energy budgets.
Impact: The success of machine learning methods in predicting neural cell and synaptic density paves the way for the use of CNNs to generate patient-specific energy budgets, improving understanding of brain energetics at a microscopic level in health and disease.
Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
FH is the founder of InnovaCyclics LLC. All other authors declare no conflict of interest.
1. Yu Y, Herman P, Rothman DL, Agarwal D, Hyder F. 2018. Evaluating the gray and white matter energy budgets of human brain function. J Cereb Blood Flow Metab. 38:1339-1353.
2. Attwell D, Laughlin SB. 2001. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. 21:1133-1145.
3. Ferree TC, Luu P, Russell GS, Tucker DM. 2001. Scalp electrode impedance, infection risk, and EEG data quality. Clin Neurophysiol. 112:536-544.
4. Wendel K, Vaisanen O, Malmivuo J, Gencer NG, Vanrumste B, Durka P, Magjarevic R, Supek S, Pascu ML, Fontenelle H, Grave de Peralta Menendez R. 2009. EEG/MEG source imaging: methods, challenges, and open issues. Comput Intell Neurosci.656092.
5. Kirschstein T, Kohling R. 2009. What is the source of the EEG? Clin EEG Neurosci. 40:146-149.
6. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010 Jan 19;74(3):201-9.
7. Amunts K, Lepage C, Borgeat L, Mohlberg H, Dickscheid T, Rousseau ME, Bludau S, Bazin PL, Lewis LB, Oros-Peusquens AM, Shah NJ, Lippert T, Zilles K, Evans AC. 2013. BigBrain: an ultrahigh-resolution 3D human brain model. Science. 340:1472-1475.
8. Finnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D, Gallezot JD, Henry S, Hannestad J, Huang YY, Carson RE. 2018. Kinetic evaluation and test-retest reproducibility of [C-11]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. J Cerebr Blood F Met. 38:2041-2052.
9. D. Rueckert, L. I. Sonoda, C. Hayes, D. L. G. Hill, M. O. Leach, and D. J. Hawkes, “Nonrigid registration using free-form deformations: application to breast MR images,” IEEE Trans. Med. Imaging, vol. 18, no. 8, pp. 712–721, 1999.
Project pipeline is shown. Subject MPRAGEs were taken from ADNI and brain masked and skull-stripped using FSL. To obtain the CellDen silver standard, original BigBrain slices were linearly registered to MNI space. This template was then nonlinearly registered to subject skull-stripped MPRAGE to create personalized CellDen templates. A similar nonlinear registration process was followed to develop the SynDen templates. These templates were used as output targets for our UNet model.
Results of each model and ablation study are shown. Especially for SynDen, masking tended to improve average correlation coefficient and average Earth Mover’s Distance (EMD). In general, registration of templates to individual MPRAGEs caused a decreased correlation coefficient and a higher EMD, but the model is likely overfitting when using non-individualized templates leading to better quantitative performance on the limited dataset.
Difference images for Subject 1 are shown. The first row of images shows the difference between model prediction and silver standard for CellDen, while the second row shows the same for SynDen. Model performance is worst at the edges of the brain, most significantly at the top edge. The model is better at predicting both cell and synaptic density in gray matter compared to white matter.
Model prediction results for each subject are shown. The first row shows subject MPRAGEs. The next two rows show CellDen silver standard and predictions, respectively, while the last two rows depict the same for SynDen. CellDen and SynDen results were predicted using separate models and the silver standard templates for both CellDen and SynDen were registered to individual MPRAGEs. Without masking, some model predictions do not exactly match template shapes, especially for SynDen.
Histograms for best, average, and worst case subject results, separated by EMD metric performance. Prediction histograms are overlaid over silver standard ones. The model performs better on SynDen than CellDen, as the worst SynDen prediction is comparable to an average CellDen one. The model also misses peaks present in the template histograms, most evidently the CellDen models. This is likely reflective of the model’s poor performance on white matter.